Development of a combined live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a sucutaneous administration of a recombinant canarypoxvirus expressing FELV genes.

EU record number

B/BE/99/VW8

Treated organism

cats

Indication category

vaccination against feline leukemia virus (FELV)

Genetic modification

env and gag genes of the type A virus of feline leukemia (FELV)

Method of transfer of nucleic acid of interest

Canarypoxvirus (ALVAC clone)

Route of administration

subcutaneous

Locations in Belgium

Heverlee, Deurne, Merksem, Tournai, Haine St Pierre, Ternat, Boncelles, Beaufays, Mechelen, Alleur

Nr of subjects

800

Foreseen duration

8 months

Type of procedure

Deliberate release only

Notes

Same genetically modified virus as for dossier B/BE/97/VW9 authorized in 1998

Information for the public

B/BE/99/VW8 - Public information sheet (written by the notifier)

B/BE/99/VW8 - Fiche d'information destinée au public (préparée par le notifiant)

B/BE/99/VW8 – Informatie fiche bestemd voor het publiek (voorbereid door de kennisgever)

Information related to the decision procedure

B/BE/99/VW8 – Advice of the Division Biosafety and Biotechnology (SBB)

6 October 2000: The SBB issues a positive advice for this trial (the advice is written in French)

B/BE/99/VW8 – Advice of the Regional Competent Authority

17 October 2000: The Regional Competent Minister issues a positive advice

B/BE/99/VW8 - Decision of the Federal Public Service (FINAL DECISION)

24 October 2000: The Federal Public Service Health, Food chain safety and Environment gives a final decision (positive with conditions) for this trial.